Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Cardiovascular risk reduction alongside weight loss: Semaglutide
doi: 10.1210/jc.2008-0751 103 HaqqLMcFarlaneJDiebergGSmartN
The 2026 update from National Institute for Health and Care Excellence introduces a paradigm shift: From glucose-centric care to cardiorenalmetabolic protection New First-Line Strategy Most patients with type 2 diabetes should now receive: Modified-release metformin SGLT2 inhibitor (early combination therapy) Even without comorbidities If metformin is not tolerated: Use SGLT2 inhibitor monotherapy Why This Matters * SGLT2 inhibitors are no longer just glucose-lowering drugs: Reduce cardiovascular events Protect kidney function Improve long-term survival NICE estimates this strategy could prevent thousands of deaths Where Do DPP-4 Inhibitors Fit Now
Salehi M, et al
In the context of breast reconstruction, GLP-1 RAs may help broaden eligibility for autologous procedures such as DIEP flap reconstruction
US$ 27.16
US$ 21.61
US$ 27.60
US$ 28.35
US$ 27.15
